1. Indonesia Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
PT Enseval Putera Megatrading Tbk.

PT Enseval Putera Megatrading Tbk.

EPMT.JK
PT Enseval Putera Megatrading Tbk.ID flagIndonesia Stock Exchange
2,250.00
IDR
-20.00
- -
6.09TMarket Cap
PT Enseval Putera Megatrading Tbk.
EPMT.JK
(Indonesia Stock Exchange)

Recent

price

2,250.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
4,078.48
4,937.18
5,767.93
6,280.48
6,451.98
6,991.05
7,261.61
7,606.95
8,205.93
8,323.52
9,478.47
10,347.44
10,524.79
11,429.11
12,168.74
11,594.31
Revenue per Share
- -
134.94
148.69
171.42
188.68
201.99
205.28
191.12
241.1
214.36
251.27
313.03
312.9
254.19
273.85
291.36
283.74
Basic EPS, GAAP
- -
-60.59
-63.16
-100.46
-79.43
-66.73
-35.65
-73.49
-47.33
-116.4
-85.26
-42.63
-51.32
-70.18
-78.8
-85.32
-66.21
Free Cash Flow per Basic Share
- -
4.78
95
2
- -
5
5
5
5
90
90
200
205
205
166
179.1
- -
Dividend per Share
- -
821.49
841.39
1,007.93
1,194.89
1,391.71
1,589.97
1,774.04
2,008.23
2,130.18
2,289.31
2,399.82
2,504.59
2,550.65
2,655.96
2,765.58
2,619.41
Book Value per Share
- -
932.72
948.19
1,114.4
1,299.8
1,500.1
1,704.34
1,892.28
2,133.46
2,258.21
2,414.75
2,522.45
2,630.57
2,690.1
2,793.8
2,899.74
2,759.67
Tangible Book Value per Share
- -
2,601
2,709
2,709
2,709
2,709
2,709
2,709
2,709
2,709
2,709
2,709
2,709
2,709
2,709
2,709
2,709
Basic Weighted Avg Shares
- -
10,610,085
13,373,033
15,623,240
17,011,550
17,476,103
18,936,241
19,669,097
20,604,487
22,226,912
22,545,419
25,673,757
28,027,488
28,507,873
30,957,341
32,960,723
31,404,814
Sales/Revenue/Turnover
- -
4.19
3.84
3.98
3.79
4.05
3.6
3.28
4.07
3.36
3.4
4.03
3.92
3.18
3.17
3.16
3.19
Operating Margin (%)
- -
68,710
80,496
95,948
115,216
129,083
126,751
120,751
127,257
128,102
162,815
179,862
172,756
169,624
177,174
200,850
193,137
Depreciation Expense
- -
351,043
402,753
464,315
511,065
547,124
556,026
517,671
653,064
580,630
680,598
847,881
847,533
688,499
741,774
789,194
768,543
Net Income, GAAP
- -
24.14
25.42
25.44
25.69
25.75
25.41
24.38
24.76
27.52
22.18
21.93
23.16
22.53
22.82
22.92
22.67
Effective Tax Rate (%)
- -
3.31
3.01
2.97
3
3.13
2.94
2.63
3.17
2.61
3.02
3.3
3.02
2.42
2.4
2.39
2.45
Profit Margin (%)
1,315,353
1,858,179
1,890,583
2,129,607
2,535,181
3,035,189
3,577,495
3,934,422
4,517,540
4,656,649
5,006,709
5,361,197
5,625,941
5,692,284
5,821,493
6,043,725
5,819,681
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
10,688
9,080
2,914
2,365
8,426
5,925
7,207
LT Debt
1,798,592
2,435,198
2,579,670
3,031,762
3,530,726
4,070,246
4,619,981
5,130,769
5,787,855
6,129,308
6,559,456
6,846,921
7,137,626
7,297,830
7,577,641
7,866,184
7,485,456
Total Equity
- -
15.47
14.71
15.73
13.97
13.25
11.42
9.96
11.51
9.01
9.32
11.93
11.98
9.67
10.09
10.28
10.05
Return on Invested Capital (%)
- -
18
18.07
18.17
16.85
15.33
13.65
11.47
12.82
10.39
11.34
13.34
12.84
10.16
10.6
10.77
10.7
Return on Capital (%)
- -
17.92
18.24
18.54
17.13
15.62
13.77
11.36
12.75
10.36
11.37
13.35
12.76
10.06
10.52
10.75
11.05
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
97,378
82,320
287,379
LT Borrowings
1,558
1,342
1,120
LT Finance Leases
6,868
6,482
6,087
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,709
2,709
2,709
Market Capitalization
6,581,995
5,796,490
6,121,526

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
9,610,395
10,807,228
10,447,051
Cash, Cash Equivalents & STI
687,659
354,284
533,613
Accounts Receivable, Net
4,216,690
5,258,420
4,976,726
Inventories
3,940,850
4,353,569
4,181,405
Total Current Liabilities
3,788,902
4,678,455
4,627,370
Payables & Accruals
- -
- -
- -
ST Debt
97,378
82,320
287,379
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.88%
3.7%
3.81%
Free Cash Flow
17.08%
5.54%
8.27%
Net Income, GAAP
4.69%
3.98%
6.39%
Sales/Revenue/Turnover
6.61%
7.96%
6.47%
Total Cash Common Dividend
- -
- -
7.89%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,976,519
7,632,776
7,580,859
7,767,187
30,957,341
2025
8,307,892
7,748,876
8,525,994
- -
32,960,723
2026
9,057,133
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
102.98
- -
- -
- -
273.85
2025
103.74
- -
- -
- -
291.36
2026
98.79
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
166
2025
- -
- -
- -
- -
179.1
2026
- -
- -
- -
- -
- -
Similar Companies
Covetrus, Inc. (CVET)
IVD Medical Holding Limited (1931.HK)
Sigma Healthcare Limited (SIG.AX)
Patterson Companies, Inc. (PDCO)
Mono Pharmacare Limited (MONOPHARMA.NS)
Checkpoint Trends Limited (CHECKPOINT.BO)
Business
PT Enseval Putera Megatrading Tbk is an integrated healthcare distribution and logistics company headquartered in Jakarta Timur, Indonesia, founded in 1973. The company operates primarily in Indonesia and is the largest pharmaceutical distributor in the country, serving pharmaceutical, consumer products, medical equipment, cosmetics, and other health-related sectors. Its core products and services include the distribution and supply of pharmaceutical products; consumer health products; medical devices and hospital supplies; raw materials for pharmaceutical, food, cosmetics, and veterinary drugs industries; and consumables for hemodialysis therapy. Additionally, Enseval provides healthcare services including drug stores, healthcare clinics, and hemodialysis clinics. The company operates an extensive logistics network, including cold chain logistics and temperature-controlled warehouse services, and offers digital platforms such as EMOS, a business-to-business order management system, and MOSTRANS, an online transportation management platform enhancing supply chain collaboration. PT Enseval Putera Megatrading operates through various subsidiaries including PT Tri Sapta Jaya (distribution of medicines, medical devices, and consumer goods), PT Global Chemindo Megatrading (distribution of raw materials), PT Enseval Medika Prima (marketing services for medical devices and diagnostics), PT Renalmed Tiara Utama (hemodialysis services and supplies), PT Forsta Kalmedic Global (medical device manufacturing), and PT Emos Global (digital platform management). The company is a subsidiary of PT Kalbe Farma Tbk, one of Indonesia’s leading pharmaceutical companies. Recent major developments include ongoing expansion in digital service platforms to enhance integrated business solutions, further enhancing efficiency in logistics and distribution operations. The firm continues investing in technology-driven platforms to streamline pharmaceutical and consumer health product ordering and transportation management. It has expanded its branch network to 48 locations across Indonesia, reinforcing its domestic distribution capabilities. Enseval also strengthened capital investment partnerships, such as increasing authorized capital in associated ventures as part of its growth strategy in the health sector over the past 1-2 years. PT Enseval Putera Megatrading Tbk’s comprehensive product portfolio and integrated logistics services position it as a vital player in Indonesia’s healthcare supply chain, targeting pharmaceutical companies, healthcare providers, clinics, hospitals, and consumer health markets throughout the archipelago. The company’s focus on cold chain logistics, healthcare clinics, and digital platforms support its competitive advantage within the health distribution and logistics industry in Indonesia.